ACURATE neo2™ Post Market Clinical Follow up Study
Study Details
Study Description
Brief Summary
The ACURATE Neo2 PMCF is aimed at collecting clinical and device performance outcomes data with the ACURATE neo2™ Transfemoral Aortic Valve System as used in routine clinical practice for the treatment of severe calcific aortic stenosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
ACURATE neo2 PMCF is a prospective, open-label, single-arm, multicenter, observational post-market surveillance study. All subjects deemed treatable with the ACURATE neo2 valve will be approached to participate in the study.
A subject who provides an Informed Consent Form (ICF) approved by the Independent Ethics Committee (IEC) and signed by the subject or the subject's legally authorized representative is considered enrolled once an attempt is made to insert the commercially available ACURATE neo2 Transfemoral Delivery System. Approximately 200 subjects will be enrolled.
Follow-up will occur at pre-discharge, 30 days, 1 year, and then annually from 2 through 5 years post index procedure per standard of care. Visits are in-person through 1 year and in-person (preferred) or via telephone interview in years 2 through 5. All subjects will undergo 4D computed tomography (CT) imaging at 30 days and 1 year.
ACURATE neo2 PMCF Study Design Overview Abbreviations: CT=computed tomography; ICF=Informed Consent Form
Study Design
Outcome Measures
Primary Outcome Measures
- Primary Safety Endpoint: [30 days]
All-cause mortality after the index implant procedure
- Primary Imaging Endpoint: [30 days]
Hypoattenuated leaflet thickening (HALT) as measured by 4D CT
Secondary Outcome Measures
- Safety endpoints adjudicated by an independent Clinical Events Committee [all 5 years]
All-cause mortality (cardiovascular and non-cardiovascular) Stroke (disabling and non-disabling) Bleeding (life-threatening [or disabling] and major) Vascular complications (major) Hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV)
- Additional Safety Endpoints [all 5 years]
Myocardial infarction (periprocedural [≤72 hours post index procedure] and spontaneous [>72 hours post index procedure]) Acute kidney injury (≤7 days post index procedure) based on the AKIN System Stage 3 (including renal replacement therapy) and Stage 2 Repeat procedure for valve-related dysfunction (surgical or interventional therapy) New permanent pacemaker implantation resulting from new or worsened conduction disturbances New onset of atrial fibrillation or atrial flutter Coronary obstruction (≤3 days post index procedure) Ventricular septal perforation (≤3 days post index procedure) Annular rupture (≤3 days post index procedure) Cardiac tamponade (≤3 days post index procedure) Valve migration Valve embolization Ectopic valve deployment Transcatheter aortic valve (TAV)-in-TAV deployment Prosthetic aortic valve thrombosis Prosthetic aortic valve endocarditis
- Prosthetic Aortic Valve Performance as measured by transthoracic echocardiography (TTE) [Discharge, 30 days, annually from year 1 to 5]
Effective orifice area (EOA), Mean and Peak aortic gradients, peak aortic velocity, and grade of aortic regurgitation/paravalvular leak (PVL). Center-reported TTE measures will also be collected annually at 2 through 5 years per local standard of care for TAVI.
- EuroQoL Quality of Life questionnaire (EQ-5D-5L) [Baseline, 30-day, 1-year]
Health status as evaluated by the EQ-5D-5L Quality Of Life questionnaire
- New York Heart Association (NYHA) functional classification [Baseline, Discharge, 30 days, annually from year 1 to 5]
Classification of heart failure symptoms as evaluated by NYHA classification
- Assessments using 4D CT-scan [30 days 1 year]
Assessment of leaflet mobility Assessment of hypoattenuated leaflet thickening (HALT) Assessment of leaflet thrombosis
Eligibility Criteria
Criteria
Inclusion Criteria:
There are no specific inclusion criteria set for this post-market surveillance study. A subject must sign an IEC-approved ICF and the ACURATE neo2 Transfemoral Aortic Valve System should be used according to the commercial IFU.
Exclusion Criteria:
EC1. Subject has a previous bioprosthesis in the aortic position.
EC2. Subject has eGFR <30 mL/min (chronic kidney disease stage IV or stage V).
EC3. Subject has atrial fibrillation that cannot be rate controlled to ventricular response rate < 60 bpm.
EC4. Subject is expected to undergo chronic anticoagulation therapy after the TAVI procedure
Note : Subjects treated with short-term anticoagulation post-procedure can be included; in these subjects the 30-day imaging will be performed 30 days after discontinuation of anticoagulation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aarhus Universitetshospital | Aarhus | Denmark | ||
| 2 | Rigshospitalet | Copenhagen | Denmark | ||
| 3 | Odense University Hospital | Odense | Denmark | ||
| 4 | Kerckhoff-Klinik GmbH Herz und Thorax Zentrum Abteilung Kardiologie/Kardiochirurgie | Bad Nauheim | Germany | ||
| 5 | HDZ Bad Oeynhausen | Bad Oeynhausen | Germany | ||
| 6 | St.-Johannes-Hospital | Dortmund | Germany | ||
| 7 | Universitätsklinik Regensburg | Regensburg | Germany | ||
| 8 | A.O.U Policlinico "G.Rodolico - San Marco" | Catania | CA | Italy | 95123 |
| 9 | San Raffaele Hospital | Milano | Italy | ||
| 10 | Azienda Ospedaliera Pisana | Pisa | Italy | ||
| 11 | Erasmus Medical Center | Rotterdam | Netherlands | ||
| 12 | UMC Utrecht | Utrecht | Netherlands | ||
| 13 | Hospital Clinico de Santiago | Santiago De Compostela | Spain | ||
| 14 | Hospital Clinico Universitario Valladolid | Valladolid | Spain | 47005 | |
| 15 | Lund University, Cardiology department | Lund | Sweden | ||
| 16 | Karolinska Universitetssjukhuset | Stockholm | Sweden | ||
| 17 | Universitätsspital Zürich | Zürich | Switzerland | ||
| 18 | Liverpool Heart and Chest Hospital | Liverpool | United Kingdom | ||
| 19 | John Radcliffe Hospital | Oxford | United Kingdom |
Sponsors and Collaborators
- Boston Scientific Corporation
Investigators
- Principal Investigator: Lars Søndergaard, Prof., Rigshospitalet, Denmark
- Principal Investigator: Won-Keun Kim, MD, Kerckhoff Klinik
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- S2410